CN105189506A - 用于治疗寄生虫疾病的化合物和组合物 - Google Patents
用于治疗寄生虫疾病的化合物和组合物 Download PDFInfo
- Publication number
- CN105189506A CN105189506A CN201380065714.4A CN201380065714A CN105189506A CN 105189506 A CN105189506 A CN 105189506A CN 201380065714 A CN201380065714 A CN 201380065714A CN 105189506 A CN105189506 A CN 105189506A
- Authority
- CN
- China
- Prior art keywords
- phenyl
- pyrazine
- methyl
- imidazo
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *c1cnc(*)cc1 Chemical compound *c1cnc(*)cc1 0.000 description 35
- ZEKBKTMMBLWNGK-UHFFFAOYSA-N CC(C)(C)c1nnn[nH]1 Chemical compound CC(C)(C)c1nnn[nH]1 ZEKBKTMMBLWNGK-UHFFFAOYSA-N 0.000 description 1
- OGDPVERFWFLZHA-UHFFFAOYSA-N CC(C)SC(C)C(C)N Chemical compound CC(C)SC(C)C(C)N OGDPVERFWFLZHA-UHFFFAOYSA-N 0.000 description 1
- ZICRALLMHKILDG-UHFFFAOYSA-N CC(C)c1n[nH]cc1 Chemical compound CC(C)c1n[nH]cc1 ZICRALLMHKILDG-UHFFFAOYSA-N 0.000 description 1
- IHEQAKZPAFNFSA-RWHTWPBISA-N CC1(/C=N\C(\C(N(C)c(cc2)ccc2F)=O)=C/C)NC(c2ccc3[n](C)ncc3c2)=CN1 Chemical compound CC1(/C=N\C(\C(N(C)c(cc2)ccc2F)=O)=C/C)NC(c2ccc3[n](C)ncc3c2)=CN1 IHEQAKZPAFNFSA-RWHTWPBISA-N 0.000 description 1
- SEVQLWITECQUHH-ZHZULCJRSA-N CCCc1ncc(-c(cc2)ccc2-c2nnc[s]2)[n]1/C=C(/C(N(C)C(CC1)=CC=C1Cl)=O)\N Chemical compound CCCc1ncc(-c(cc2)ccc2-c2nnc[s]2)[n]1/C=C(/C(N(C)C(CC1)=CC=C1Cl)=O)\N SEVQLWITECQUHH-ZHZULCJRSA-N 0.000 description 1
- OVRVQGZHQUPWQA-UHFFFAOYSA-N CCOc1cc(N(C)C(C(N=CC2=C3)=CN2C(c2ccc(C(F)(F)F)cc2)=CC3=C)=O)ncc1 Chemical compound CCOc1cc(N(C)C(C(N=CC2=C3)=CN2C(c2ccc(C(F)(F)F)cc2)=CC3=C)=O)ncc1 OVRVQGZHQUPWQA-UHFFFAOYSA-N 0.000 description 1
- OLGOTNLCPQXGLS-UHFFFAOYSA-N CC[n]1ncc(C)c1 Chemical compound CC[n]1ncc(C)c1 OLGOTNLCPQXGLS-UHFFFAOYSA-N 0.000 description 1
- GAKXENQAPIJXRU-JXAWBTAJSA-N CCc1ncc(-c2ccc(C(F)(F)F)cc2)[n]1/C=C(/C(N(C)c1ccc(N(C)C)nc1)=O)\N Chemical compound CCc1ncc(-c2ccc(C(F)(F)F)cc2)[n]1/C=C(/C(N(C)c1ccc(N(C)C)nc1)=O)\N GAKXENQAPIJXRU-JXAWBTAJSA-N 0.000 description 1
- VGBQOAPZAJFNSL-UHFFFAOYSA-N CN(C(C1=C[n]2c(-c3ccnc(Cl)c3)cnc2CC1)=O)c(cc1)ccc1C#N Chemical compound CN(C(C1=C[n]2c(-c3ccnc(Cl)c3)cnc2CC1)=O)c(cc1)ccc1C#N VGBQOAPZAJFNSL-UHFFFAOYSA-N 0.000 description 1
- AMZITDJEKRWENH-UHFFFAOYSA-N CN(C(c(nc1)c[n]2c1ncc2-c(cc1)ccc1C1=NN=CC1)=O)c(cc1)ccc1F Chemical compound CN(C(c(nc1)c[n]2c1ncc2-c(cc1)ccc1C1=NN=CC1)=O)c(cc1)ccc1F AMZITDJEKRWENH-UHFFFAOYSA-N 0.000 description 1
- DYCDLWSHAFQOQS-UHFFFAOYSA-N CN(C)CCN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)C(C=C1)=CC1C#N Chemical compound CN(C)CCN(C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O)C(C=C1)=CC1C#N DYCDLWSHAFQOQS-UHFFFAOYSA-N 0.000 description 1
- NPDBDURRDSIKQD-UHFFFAOYSA-N CN(C)c(nc1)ccc1-c1cnc2[n]1cc(C(N(C)c(cn1)ccc1Cl)=O)nc2 Chemical compound CN(C)c(nc1)ccc1-c1cnc2[n]1cc(C(N(C)c(cn1)ccc1Cl)=O)nc2 NPDBDURRDSIKQD-UHFFFAOYSA-N 0.000 description 1
- SOXRHKNYYSNEAZ-UHFFFAOYSA-N CN(Cc(nc1)c[n]2c1ncc2Br)c(cc1)ccc1C#N Chemical compound CN(Cc(nc1)c[n]2c1ncc2Br)c(cc1)ccc1C#N SOXRHKNYYSNEAZ-UHFFFAOYSA-N 0.000 description 1
- YDYWIJGHXKMAHB-UHFFFAOYSA-N CNC(C(CC1)=CC=C1c1cnc2[n]1cc(C(N1c(ccc(F)c3)c3OCC1)=O)nc2)=O Chemical compound CNC(C(CC1)=CC=C1c1cnc2[n]1cc(C(N1c(ccc(F)c3)c3OCC1)=O)nc2)=O YDYWIJGHXKMAHB-UHFFFAOYSA-N 0.000 description 1
- KFKXBRFAEDEHBI-UHFFFAOYSA-N CNC(c1ccc(C2N(CC(C(N(CI)C(C=C3)=CCC=C3Cl)=O)N=C3)C3=NC2)cc1)=O Chemical compound CNC(c1ccc(C2N(CC(C(N(CI)C(C=C3)=CCC=C3Cl)=O)N=C3)C3=NC2)cc1)=O KFKXBRFAEDEHBI-UHFFFAOYSA-N 0.000 description 1
- HLYMRJOVXOPJHQ-LCYFTJDESA-N COC(/C(/N)=C/[n]1c(-c2ccc(C(F)(F)F)cc2)cnc1C1CC1)=O Chemical compound COC(/C(/N)=C/[n]1c(-c2ccc(C(F)(F)F)cc2)cnc1C1CC1)=O HLYMRJOVXOPJHQ-LCYFTJDESA-N 0.000 description 1
- ROBQKMKHRZINIJ-UHFFFAOYSA-O C[NH+]1C2C1CC2 Chemical compound C[NH+]1C2C1CC2 ROBQKMKHRZINIJ-UHFFFAOYSA-O 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N C[n]1cncc1 Chemical compound C[n]1cncc1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- HHPIVZLMDVERHJ-UHFFFAOYSA-N Cc(nc1)cnc1N(C)C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O Chemical compound Cc(nc1)cnc1N(C)C(c(nc1)c[n]2c1ncc2-c1ccc(C(F)(F)F)cc1)=O HHPIVZLMDVERHJ-UHFFFAOYSA-N 0.000 description 1
- LSZQMSSIUQNTDX-UHFFFAOYSA-N Cc1ccn[n]1C Chemical compound Cc1ccn[n]1C LSZQMSSIUQNTDX-UHFFFAOYSA-N 0.000 description 1
- PEUUDVCRSCULKR-UHFFFAOYSA-N Cc1cnc(C2N(C=C(C(N(C)c(cc3)csc3C#N)=O)NC3)C3=NC2)cc1 Chemical compound Cc1cnc(C2N(C=C(C(N(C)c(cc3)csc3C#N)=O)NC3)C3=NC2)cc1 PEUUDVCRSCULKR-UHFFFAOYSA-N 0.000 description 1
- MJVZSRZTBDMYLX-UHFFFAOYSA-N Nc(ccc(Cl)n1)c1Cl Chemical compound Nc(ccc(Cl)n1)c1Cl MJVZSRZTBDMYLX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728024P | 2012-11-19 | 2012-11-19 | |
| US61/728,024 | 2012-11-19 | ||
| PCT/US2013/070623 WO2014078813A1 (en) | 2012-11-19 | 2013-11-18 | Compounds and compositions for the treatment of parasitic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105189506A true CN105189506A (zh) | 2015-12-23 |
Family
ID=49667633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380065714.4A Pending CN105189506A (zh) | 2012-11-19 | 2013-11-18 | 用于治疗寄生虫疾病的化合物和组合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150291598A1 (enExample) |
| EP (1) | EP2920177A1 (enExample) |
| JP (1) | JP2016500073A (enExample) |
| CN (1) | CN105189506A (enExample) |
| WO (1) | WO2014078813A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110168093A (zh) * | 2017-09-12 | 2019-08-23 | 广州中科蓝华生物科技有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| CN110809577A (zh) * | 2017-06-30 | 2020-02-18 | 雷沃医疗有限公司 | 腺苷a2a受体的调节剂 |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189506A (zh) * | 2012-11-19 | 2015-12-23 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
| WO2014078802A1 (en) | 2012-11-19 | 2014-05-22 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| CA2952895C (en) * | 2014-06-25 | 2023-09-26 | F. Hoffmann-La Roche Ag | Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy |
| EA032416B1 (ru) | 2014-12-23 | 2019-05-31 | Новартис Аг | Соединения триазолопиримидина и их применения |
| CN104610229B (zh) * | 2015-01-21 | 2017-01-18 | 上海皓元生物医药科技有限公司 | 一种是atp竞争性小分子akt抑制剂a443654的合成方法 |
| EP3472168B1 (en) | 2016-06-20 | 2024-01-10 | Novartis AG | Crystalline forms of triazolopyrimidine compound |
| US10676479B2 (en) | 2016-06-20 | 2020-06-09 | Novartis Ag | Imidazolepyridine compounds and uses thereof |
| WO2017221092A1 (en) | 2016-06-20 | 2017-12-28 | Novartis Ag | Triazolopyridine compounds and uses thereof |
| GB201700692D0 (en) * | 2017-01-16 | 2017-03-01 | Salvensis | Novel compounds and their use in the treatment of schistosomiasis |
| JP6818131B2 (ja) * | 2017-04-27 | 2021-01-20 | 日本農薬株式会社 | 縮合複素環化合物又はその塩類、及びそれらの化合物を含有する農園芸用殺虫剤並びにその使用方法 |
| WO2018237349A1 (en) * | 2017-06-23 | 2018-12-27 | University Of Washington | Inhibitors of typed 1 methionyl-trna synthetase and methods of using them |
| KR20200115620A (ko) | 2018-01-29 | 2020-10-07 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| GB201811695D0 (en) | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
| CA3104054A1 (en) | 2018-08-21 | 2020-02-27 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic heteroaromatic ring derivative |
| BR112021007421A2 (pt) | 2018-12-06 | 2021-08-03 | Daiichi Sankyo Company, Limited | derivado de cicloalcano-1,3-diamina |
| EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | CHEMICAL COMPOUNDS |
| CA3128346A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| BR112022007404A2 (pt) * | 2019-10-21 | 2022-07-05 | Novartis Ag | Compostos e composições para o tratamento de doenças parasíticas |
| WO2024022910A1 (en) | 2022-07-26 | 2024-02-01 | Syngenta Crop Protection Ag | 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-dichloro-5-phenyl]urea derivatives and similar compounds as pesticides |
| EP4695245A1 (en) * | 2023-04-13 | 2026-02-18 | Syngenta Crop Protection AG | Imidazo[1,2-a]pyridine derivatives |
| TW202446263A (zh) * | 2023-04-13 | 2024-12-01 | 瑞士商先正達農作物保護股份公司 | 殺真菌組成物 |
| EP4695246A1 (en) * | 2023-04-13 | 2026-02-18 | Syngenta Crop Protection AG | Imidazo[1,2-a]pyridine derivatives |
| PY2426847A (es) * | 2023-04-13 | 2025-03-20 | Syngenta Crop Prot Ag | Derivados bicíclicos de imidazo |
| AR132352A1 (es) * | 2023-04-13 | 2025-06-18 | Syngenta Crop Protection Ag | Derivados de imidazo[1,2-a]pirazina |
| CN120957990A (zh) * | 2023-04-13 | 2025-11-14 | 先正达农作物保护股份公司 | 咪唑并[1,2-a]吡啶衍生物 |
| WO2026018203A1 (en) * | 2024-07-19 | 2026-01-22 | Novartis Ag | Aminoisoquinoline compounds and methods of using thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| EP2124954A2 (en) * | 2007-01-26 | 2009-12-02 | Irm Llc | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases |
| TWI421252B (zh) * | 2009-07-09 | 2014-01-01 | Irm Llc | 用於治療寄生蟲疾病之化合物及組合物 |
| CN105189506A (zh) * | 2012-11-19 | 2015-12-23 | 诺华股份有限公司 | 用于治疗寄生虫疾病的化合物和组合物 |
-
2013
- 2013-11-18 CN CN201380065714.4A patent/CN105189506A/zh active Pending
- 2013-11-18 WO PCT/US2013/070623 patent/WO2014078813A1/en not_active Ceased
- 2013-11-18 JP JP2015543098A patent/JP2016500073A/ja active Pending
- 2013-11-18 US US14/443,604 patent/US20150291598A1/en not_active Abandoned
- 2013-11-18 EP EP13795980.5A patent/EP2920177A1/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110809577A (zh) * | 2017-06-30 | 2020-02-18 | 雷沃医疗有限公司 | 腺苷a2a受体的调节剂 |
| CN110168093A (zh) * | 2017-09-12 | 2019-08-23 | 广州中科蓝华生物科技有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
| CN110168093B (zh) * | 2017-09-12 | 2023-08-15 | 中科蓝华(广州)生物医药技术有限公司 | 一种转染细胞内寄生虫的试剂盒及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2920177A1 (en) | 2015-09-23 |
| JP2016500073A (ja) | 2016-01-07 |
| WO2014078813A1 (en) | 2014-05-22 |
| US20150291598A1 (en) | 2015-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105189506A (zh) | 用于治疗寄生虫疾病的化合物和组合物 | |
| TWI869519B (zh) | Sos1抑制劑 | |
| TWI868441B (zh) | 非環氧氮呯化合物及其用途 | |
| US20240025919A1 (en) | Aza-tetracyclic oxazepine compounds and uses thereof | |
| CN102203067B (zh) | Hedgehog通路调节剂 | |
| WO2023064857A1 (en) | Quinoline compounds as inhibitors of kras | |
| JP6298472B2 (ja) | 寄生虫病の処置のための化合物および組成物 | |
| JP2025535367A (ja) | ６－アザ部分を含むオキサゼピン化合物およびその使用 | |
| CN115485278A (zh) | 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法 | |
| CN108026105B (zh) | TGFβ受体拮抗剂 | |
| TW201522342A (zh) | 用於治療寄生蟲疾病之化合物及組合物 | |
| KR20170075756A (ko) | 카르바졸 유도체 | |
| TWI879771B (zh) | 三環類化合物及其用途 | |
| JP2020537692A (ja) | ヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びその使用方法 | |
| WO2014151630A2 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| JP6392352B2 (ja) | リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体 | |
| CN107922407A (zh) | 呼吸道合胞病毒抑制剂 | |
| TW202216712A (zh) | 一種高活性的ｈｐｋ１激酶抑制劑 | |
| CN114127080B (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| CN112209925A (zh) | Ret选择性抑制剂及其制备方法和用途 | |
| TWI768781B (zh) | 轉化生長因子－β受體抑制劑 | |
| WO2023169170A1 (zh) | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| CN119053596A (zh) | 作为激酶抑制剂的杂环化合物、其组合物及使用方法 | |
| HK40099028A (zh) | 氧氮杂䓬化合物及其在癌症治疗中的用途 | |
| CN121443604A (zh) | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| AD01 | Patent right deemed abandoned | ||
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20180302 |